Results 31 to 40 of about 7,554 (201)

HVEM has a broader expression than PD-L1 and constitutes a negative prognostic marker and potential treatment target for melanoma

OncoImmunology, 2019
HVEM (Herpes Virus Entry Mediator) engagement of BTLA (B and T Lymphocyte Attenuator) triggers inhibitory signals in T cells and could play a role in evading antitumor immunity.
Nausicaa Malissen, Nicolas Macagno, Samuel Granjeaud, Clémence Granier, Vincent Moutardier, Caroline Gaudy-Marqueste, Nadia Habel, Marion Mandavit, Bernard Guillot, Christine Pasero, Eric Tartour, Robert Ballotti, Jean-Jacques Grob, Daniel Olive   +13 more
doaj   +1 more source

BTLA stimulation protects against atherosclerosis by regulating follicular B cells [PDF]

, 2019
The immune system is strongly involved in atherosclerosis and immune regulation generally leads to attenuated atherosclerosis. B and T lymphocyte attenuator (BTLA) is a novel co-receptor that negatively regulates the activation of B and T cells, however,
Kuiper, J., Wezel, A., Smeets, H., Yagita, H., Depuydt, M.A.C., Schaftenaar, F.H., Kleijn, M.N.A.B., Kröner, M.J., Binder, C.J., Slütter, B.A., Puijvelde, G.H.M. van, Amersfoort, J., Kiss, M.B., Bernabé Kleijn, M.N.A., Bot, I., Foks, A.C., Douna, H., Slütter, B.   +17 more
core   +1 more source

DataSheet_1_High BTLA Expression Likely Contributes to Contraction of the Regulatory T Cell Subset in Lupus Disease.pdf

, 2021
B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor that is expressed by lymphoid cells and regulates the immune response. Consistent with an inhibitory role for BTLA, the disease is exacerbated in BTLA-deficient lupus mice.
Renaud Felten (6392990), Lucie Aubergeon (11754911), Matthieu Sawaf (11754914), Fanny Monneaux (70082), Jacques-Eric Gottenberg (63789), Hélène Dumortier (270522)   +5 more
core   +1 more source

Lymphocyte HVEM/BTLA co-expression after critical illness demonstrates severity indiscriminate upregulation, impacting critical illness-induced immunosuppression

Frontiers in Medicine, 2023
IntroductionThe co-regulatory molecule, HVEM, can stimulate or inhibit immune function, but when co-expressed with BTLA, forms an inert complex preventing signaling.
Michelle E. Wakeley, Brandon E. Armstead, Brandon E. Armstead, Chyna C. Gray, Chyna C. Gray, Elizabeth W. Tindal, Daithi S. Heffernan, Chun-Shiang Chung, Alfred Ayala   +8 more
doaj   +1 more source

Papel de BTLA en el eje cardio-renal [PDF]

, 2023
La malaltia cardiovascular (MCV) és la causa principal de mort en pacients amb malaltia renal crònica (MRC), destacant la inflamació persistent com a punt d'unió entre ambdues malalties.
Doladé Masot, Nuria
core  

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia [PDF]

, 2021
Chronic lymphocytic leukemia (CLL) is characterized by progressive immunosuppression and diminished cancer immunosurveillance. Immune checkpoint blockade (ICB)-based therapies, a major breakthrough against cancer, have emerged as a powerful tool to ...
Seila Lorenzo-Herrero, González Rodríguez, Ana Pilar, González Rodríguez, Segundo, Sordo Bahamonde, Christian, Ramírez Payer, Ángel, Ana P Gonzalez-Rodriguez, Alejandro López-Soto, Lorenzo Herrero, Seila, Segundo Gonzalez, González-García E., Esther González-García, López Soto, Alejandro, Christian Sordo-Bahamonde, Ángel R. Payer   +13 more
core   +1 more source

Dissection of BTLA Interactomes Using Cell Free Reconstitution [PDF]

, 2018
B and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor expressed on T cells and B cells that is structurally and functionally related to programmed death protein-1 (PD-1), a well-established cancer immunotherapy target.
Wu, Zijun
core   +1 more source

Altered BTLA expression and function in lymphocytes during lupus: consequences for therapeutic targeting

, 2023
International audienceB and T lymphocyte attenuator (BTLA) is a co-inhibitory receptor expressed by lymphoid cells that negatively regulates the immune response.
Gherardi, Léa, Dumortier, Hélène, Monneaux, Fanny   +2 more
core   +1 more source

BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes

Journal for ImmunoTherapy of Cancer, 2019
Background The standard treatment for epithelial ovarian carcinoma (EOC) is surgery followed by platinum/paclitaxel-based chemotherapy, but the overall survival rate is poor.
Yu-Li Chen, Han-Wei Lin, Chung-Liang Chien, Yen-Ling Lai, Wei-Zen Sun, Chi-An Chen, Wen-Fang Cheng   +6 more
doaj   +1 more source

Charakterisierung und funktionelle Bedeutung der BTLA-HVEM-Interaktion für die Immunantwort [PDF]

, 2010
Interaktionen zwischen Zellen sowie deren Aktivierung werden im Immunsystem durch verschiedene Zelloberflächenmoleküle reguliert. Inhalt dieser Arbeit war die Untersuchung des kürzlich identifizierten Rezeptor-Ligand-Paares BTLA und HVEM. Zunächst wurden
Gurka, Stephanie
core   +1 more source